Loading company…
MeaCor develops minimally invasive transcatheter devices to treat heart valve disease.
Founded in 2016 and based in Ayer, US, MeaCor develops transcatheter devices for mitral and tricuspid valve regurgitation. Its CryoCinch system uses cryo-adhesion to attach repair anchors as an alternative to open-heart surgery. In May 2024, MeaCor raised USD 15 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in